Insulin-like growth factor binding protein-3 generation as a measure of GH sensitivity

C. K. Buckway, K. A. Selva, K. L. Pratt, E. Tjoeng, J. Guevara-Aguirre, Ronald (Ron) Rosenfeld

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

A total of 198 subjects were randomized to either high-dose (0.05 mg/kg·d) or low-dose (0.025 mg/kg·d) GH for 7 d; the alternate dose was then received after a 2-wk washout period. Groups included in the study were: normal, GH-insensitive (GHI; homozygous for the E180 splice mutation); heterozygous GHI (carriers of the E180 splice mutation); GH-deficient; and idiopathic short stature. Serum IGF binding protein-3 (IGFBP-3) concentrations (collected on d 1, 5, and 8 of treatment weeks) were GH-dependent, with significant elevation by d 5 of treatment, regardless of dose, in all normal subjects. GHI subjects had low baseline IGFBP-3 and poor or no response to either low-or high-dose GH. Heterozygous subjects, however, did not differ from age-matched normals with regard to IGFBP-3 generation. All GH-deficient subjects had subnormal baseline concentrations of IGFBP-3; most, but not all, were able to generate levels into normal ranges by 8 d of therapy. Children with idiopathic short stature showed a better response in IGFBP-3 generation compared with that previously observed with IGF-I, reaching concentrations in normal range with either dose of GH, suggesting that any GHI in this group is relatively limited to IGF-I production. For the diagnosis of GHI, the highest sensitivity (100%) and specificity (92%) was found on d 8 of the high-dose GH-IGFBP-3 generation test. Failure to raise both IGF-I and IGFBP-3 lowered sensitivity to 82-86% with low-dose GH, and 86-91% with high-dose GH.

Original languageEnglish (US)
Pages (from-to)4754-4765
Number of pages12
JournalJournal of Clinical Endocrinology and Metabolism
Volume87
Issue number10
DOIs
StatePublished - Oct 1 2002
Externally publishedYes

Fingerprint

Insulin-Like Growth Factor Binding Protein 3
Insulin-Like Growth Factor I
Reference Values
Mutation
Blood Proteins
Therapeutics
Sensitivity and Specificity

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Buckway, C. K., Selva, K. A., Pratt, K. L., Tjoeng, E., Guevara-Aguirre, J., & Rosenfeld, R. R. (2002). Insulin-like growth factor binding protein-3 generation as a measure of GH sensitivity. Journal of Clinical Endocrinology and Metabolism, 87(10), 4754-4765. https://doi.org/10.1210/jc.2002-020045

Insulin-like growth factor binding protein-3 generation as a measure of GH sensitivity. / Buckway, C. K.; Selva, K. A.; Pratt, K. L.; Tjoeng, E.; Guevara-Aguirre, J.; Rosenfeld, Ronald (Ron).

In: Journal of Clinical Endocrinology and Metabolism, Vol. 87, No. 10, 01.10.2002, p. 4754-4765.

Research output: Contribution to journalArticle

Buckway, CK, Selva, KA, Pratt, KL, Tjoeng, E, Guevara-Aguirre, J & Rosenfeld, RR 2002, 'Insulin-like growth factor binding protein-3 generation as a measure of GH sensitivity', Journal of Clinical Endocrinology and Metabolism, vol. 87, no. 10, pp. 4754-4765. https://doi.org/10.1210/jc.2002-020045
Buckway, C. K. ; Selva, K. A. ; Pratt, K. L. ; Tjoeng, E. ; Guevara-Aguirre, J. ; Rosenfeld, Ronald (Ron). / Insulin-like growth factor binding protein-3 generation as a measure of GH sensitivity. In: Journal of Clinical Endocrinology and Metabolism. 2002 ; Vol. 87, No. 10. pp. 4754-4765.
@article{f71e5f4179964f398e3593e97d40eca5,
title = "Insulin-like growth factor binding protein-3 generation as a measure of GH sensitivity",
abstract = "A total of 198 subjects were randomized to either high-dose (0.05 mg/kg·d) or low-dose (0.025 mg/kg·d) GH for 7 d; the alternate dose was then received after a 2-wk washout period. Groups included in the study were: normal, GH-insensitive (GHI; homozygous for the E180 splice mutation); heterozygous GHI (carriers of the E180 splice mutation); GH-deficient; and idiopathic short stature. Serum IGF binding protein-3 (IGFBP-3) concentrations (collected on d 1, 5, and 8 of treatment weeks) were GH-dependent, with significant elevation by d 5 of treatment, regardless of dose, in all normal subjects. GHI subjects had low baseline IGFBP-3 and poor or no response to either low-or high-dose GH. Heterozygous subjects, however, did not differ from age-matched normals with regard to IGFBP-3 generation. All GH-deficient subjects had subnormal baseline concentrations of IGFBP-3; most, but not all, were able to generate levels into normal ranges by 8 d of therapy. Children with idiopathic short stature showed a better response in IGFBP-3 generation compared with that previously observed with IGF-I, reaching concentrations in normal range with either dose of GH, suggesting that any GHI in this group is relatively limited to IGF-I production. For the diagnosis of GHI, the highest sensitivity (100{\%}) and specificity (92{\%}) was found on d 8 of the high-dose GH-IGFBP-3 generation test. Failure to raise both IGF-I and IGFBP-3 lowered sensitivity to 82-86{\%} with low-dose GH, and 86-91{\%} with high-dose GH.",
author = "Buckway, {C. K.} and Selva, {K. A.} and Pratt, {K. L.} and E. Tjoeng and J. Guevara-Aguirre and Rosenfeld, {Ronald (Ron)}",
year = "2002",
month = "10",
day = "1",
doi = "10.1210/jc.2002-020045",
language = "English (US)",
volume = "87",
pages = "4754--4765",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "10",

}

TY - JOUR

T1 - Insulin-like growth factor binding protein-3 generation as a measure of GH sensitivity

AU - Buckway, C. K.

AU - Selva, K. A.

AU - Pratt, K. L.

AU - Tjoeng, E.

AU - Guevara-Aguirre, J.

AU - Rosenfeld, Ronald (Ron)

PY - 2002/10/1

Y1 - 2002/10/1

N2 - A total of 198 subjects were randomized to either high-dose (0.05 mg/kg·d) or low-dose (0.025 mg/kg·d) GH for 7 d; the alternate dose was then received after a 2-wk washout period. Groups included in the study were: normal, GH-insensitive (GHI; homozygous for the E180 splice mutation); heterozygous GHI (carriers of the E180 splice mutation); GH-deficient; and idiopathic short stature. Serum IGF binding protein-3 (IGFBP-3) concentrations (collected on d 1, 5, and 8 of treatment weeks) were GH-dependent, with significant elevation by d 5 of treatment, regardless of dose, in all normal subjects. GHI subjects had low baseline IGFBP-3 and poor or no response to either low-or high-dose GH. Heterozygous subjects, however, did not differ from age-matched normals with regard to IGFBP-3 generation. All GH-deficient subjects had subnormal baseline concentrations of IGFBP-3; most, but not all, were able to generate levels into normal ranges by 8 d of therapy. Children with idiopathic short stature showed a better response in IGFBP-3 generation compared with that previously observed with IGF-I, reaching concentrations in normal range with either dose of GH, suggesting that any GHI in this group is relatively limited to IGF-I production. For the diagnosis of GHI, the highest sensitivity (100%) and specificity (92%) was found on d 8 of the high-dose GH-IGFBP-3 generation test. Failure to raise both IGF-I and IGFBP-3 lowered sensitivity to 82-86% with low-dose GH, and 86-91% with high-dose GH.

AB - A total of 198 subjects were randomized to either high-dose (0.05 mg/kg·d) or low-dose (0.025 mg/kg·d) GH for 7 d; the alternate dose was then received after a 2-wk washout period. Groups included in the study were: normal, GH-insensitive (GHI; homozygous for the E180 splice mutation); heterozygous GHI (carriers of the E180 splice mutation); GH-deficient; and idiopathic short stature. Serum IGF binding protein-3 (IGFBP-3) concentrations (collected on d 1, 5, and 8 of treatment weeks) were GH-dependent, with significant elevation by d 5 of treatment, regardless of dose, in all normal subjects. GHI subjects had low baseline IGFBP-3 and poor or no response to either low-or high-dose GH. Heterozygous subjects, however, did not differ from age-matched normals with regard to IGFBP-3 generation. All GH-deficient subjects had subnormal baseline concentrations of IGFBP-3; most, but not all, were able to generate levels into normal ranges by 8 d of therapy. Children with idiopathic short stature showed a better response in IGFBP-3 generation compared with that previously observed with IGF-I, reaching concentrations in normal range with either dose of GH, suggesting that any GHI in this group is relatively limited to IGF-I production. For the diagnosis of GHI, the highest sensitivity (100%) and specificity (92%) was found on d 8 of the high-dose GH-IGFBP-3 generation test. Failure to raise both IGF-I and IGFBP-3 lowered sensitivity to 82-86% with low-dose GH, and 86-91% with high-dose GH.

UR - http://www.scopus.com/inward/record.url?scp=0036776271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036776271&partnerID=8YFLogxK

U2 - 10.1210/jc.2002-020045

DO - 10.1210/jc.2002-020045

M3 - Article

C2 - 12364470

AN - SCOPUS:0036776271

VL - 87

SP - 4754

EP - 4765

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 10

ER -